| CAS ID: | 75847-73-3 |
| Molecular Formula: | C20H28N2O5 |
| Molecular Weight: | 376.5 g/mol |
| Monoisotopic Mass: | 376.1998 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | EDNYT | Xanef | INNOVACE | PRALENAL 10 | PRALENAL 2.5 | ENALAPRIL MALEATE | EPANED KIT | Lexxel | Vasotec | ENALAPRIL | PRALENAL 5 | VASOTEC | ENAPREN | EPANED | PRALENAL 20 | RENITEC | Vaseretic |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1 | See All |
| InChI Key: | GBXSMTUPTTWBMN-XIRDDKMYSA-N | |
| Smiles: | CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O | See All |
| Molfile: | Download |
Reference Record 1
Reference Record 2
Reference Record 3
Reference Record 4
| PubMed ID | 21565836 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 5
Reference Record 6
Reference Record 7
Trial Record 1
| ClinicalTrial ID | NCT02432885 | Disease | Cardiac fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 4, 2015 | Last Verified | May 4, 2015 |
| Sponsor | InCor Heart Institute | ||
Trial Record 2
| ClinicalTrial ID | NCT01754909 | Disease | Pulmonary fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | December 21, 2012 | Last Verified | June 6, 2018 |
| Sponsor | VA Office of Research and Development | ||